In a post-pandemic society, sponsors and research institutions have adapted to new ways of working, particularly in the conduct of clinical trials.
An outcome of the pandemic was a renewed focus on patient-centric approaches to clinical trial success. One of those approaches includes the option of home health components to provide patients more flexibility and reduce participation burden. In this session the speakers provided insights into their experience with home health visits to-date and engaged site and investigator attendees to understand what works and doesn’t work for sites when offered home health options in trial protocols.
Diana Francisco, Associate Director, Lead Study Manager, Clinical Sciences and Study Management (CSSM) – Oncology | Lung Global Clinical Trial Operations (GCTO), Merck Research Laboratories
